Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.…
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences (NYSE: RCUS) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 601 employees.
The shares were at 15.62 USD on 20 November 2026, down 21.9% over 52 weeks. Its 52-week range is 15.56 USD to 31.74 USD, and it trades at the bottom of that range.
Its market capitalisation is 2.25B USD.
Arcus Biosciences reports return on equity of -55.9%, an operating margin of -475.0% and revenue down 65.4% year over year.
It holds more cash than debt, a net cash position of 389.00M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 40.92 USD is 162.0% above the current price. The next earnings report is expected on 24 February 2027.